News

Severe posttransfusion hyperhemolysis in a sickle cell patient produced profound anemia and lactic acidosis; terminal complement blockade with eculizumab stabilized…

The Permanent Secretary at Uganda’s Ministry of Health, Diana Atwine, has pledged increased access to sickle cell treatment and stronger prevention measures as…

AbstractSickle cell-beta thalassemia, a compound heterozygous hemoglobinopathy, can be difficult to diagnose because clinical features and laboratory findings often…

AbstractBackground: Sickle cell disease is the most common genetic disorder in the world. It is a real public health problem in sub-Saharan Africa. Early screening…

Our mission is to train the next generation of providers with expertise in the care of individuals with sickle cell disease (SCD) throughout their lifespan.…

Agios Pharmaceuticals will present Phase 3 trial results for mitapivat in sickle cell disease at EHA 2026.Quiver AI SummaryAgios Pharmaceuticals announced that…

Newer oral anticoagulants, or blood thinners, were linked to a lower risk of clinically relevant nonmajor bleeding than warfarin, an older blood thinner, in adults…

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through…

Key TakeawaysAgios aligned with FDA on a 52-week, randomized, double-blind confirmatory trial (n≈159; age ≥12 years) using transfusion-free status from weeks 4–52…

ABSTRACTErythrocytaphoresis or RBC exchange (RBCX) is a key intervention in the management of sickle cell anemia for both chronic prophylaxis and emergent clinical…